Dr. Daniel Gold, President & CEO of MEI Pharma Inc (MEIP), updated investors on the status of research involving the company’s three wholly owned drug candidates: Pracinostat, ME-344 and PWT143. All are focused on treating patients with acute myeloid leukemia, myelodysplastic syndrome, or bone marrow cancer, and small cell lung and ovarian cancer respectively, Gold said.
Gold reported that Pracinostat continues to show great promise. The drug is in three trials as part of its Phase II study, he said, measuring single agent and multi-combination responses, as well as responses in older patients who are unable to manage the rigors of chemotherapy.
“We are seeing great overall rapid response,” Gold said. “We believe it’s best-in-class in terms of its prolonged activity in patients.”
FOR THE LATEST TWST PHARMACEUTICALS REPORT CLICK HERE.
For ME-344, a potent inhibitor of multiple tumor cell lines including chemo-resistant ovarian cancer cells, MEI Pharma is completing its first in-human trial with promising results, Gold said. Of the 21 patients in the trial, 38% showed stable or better results, and one lung cancer patient is now out two years cancer-free, while another seven showed SD, or best response, he said.
PWT143 was acquired from Pathway in September 2013, Gold said. He noted it is a highly selective delta inhibitor that shows potential synergies with Pracinostat for hematologic diseases.
Both Pracinostate and ME-344 have intellectual property protection beyond 2029, Gold said, and the company has $54.7 million cash, with no debt, which should fund research through 2015.
FOR THE FULL PRESENTATION CLICK HERE.
Matt Flake, President and CEO of Q2 Holdings Inc (QTWO), Presents at Canaccord Genuity Global Growth Conference
August 15, 2014
Yves J. Ribeill, President and CEO, Scynexis, Inc. (SCYX), Presents at Canaccord Genuity Growth Conference
August 18, 2014
Francois Nader, President and CEO of NPS Pharmaceuticals, Inc. (NPSP), Presents at Canaccord Genuity Growth Conference
August 19, 2014
Sanj K. Patel, President and CEO of Synageva BioPharma Corp. (GEVA), Presents at the Canaccord Genuity Growth
August 15, 2014
Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals (JAZZ), Presents at Canaccord Genuity Growth Conference
August 15, 2014
